BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23074285)

  • 1. The CRTC1-NEDD9 signaling axis mediates lung cancer progression caused by LKB1 loss.
    Feng Y; Wang Y; Wang Z; Fang Z; Li F; Gao Y; Liu H; Xiao T; Li F; Zhou Y; Zhai Q; Liu X; Sun Y; Bardeesy N; Wong KK; Chen H; Xiong ZQ; Ji H
    Cancer Res; 2012 Dec; 72(24):6502-11. PubMed ID: 23074285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin.
    Zhang W; Gao Y; Li F; Tong X; Ren Y; Han X; Yao S; Long F; Yang Z; Fan H; Zhang L; Ji H
    Cancer Res; 2015 Nov; 75(21):4450-7. PubMed ID: 26363011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NEDD9 promotes lung cancer metastasis through epithelial-mesenchymal transition.
    Jin Y; Li F; Zheng C; Wang Y; Fang Z; Guo C; Wang X; Liu H; Deng L; Li C; Wang H; Chen H; Feng Y; Ji H
    Int J Cancer; 2014 May; 134(10):2294-304. PubMed ID: 24174333
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Deneka AY; Kopp MC; Nikonova AS; Gaponova AV; Kiseleva AA; Hensley HH; Flieder DB; Serebriiskii IG; Golemis EA
    Cancer Res; 2021 Jul; 81(13):3717-3726. PubMed ID: 34006524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer.
    Kondo S; Iwata S; Yamada T; Inoue Y; Ichihara H; Kichikawa Y; Katayose T; Souta-Kuribara A; Yamazaki H; Hosono O; Kawasaki H; Tanaka H; Hayashi Y; Sakamoto M; Kamiya K; Dang NH; Morimoto C
    Clin Cancer Res; 2012 Nov; 18(22):6326-38. PubMed ID: 23037767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LKB1 modulates lung cancer differentiation and metastasis.
    Ji H; Ramsey MR; Hayes DN; Fan C; McNamara K; Kozlowski P; Torrice C; Wu MC; Shimamura T; Perera SA; Liang MC; Cai D; Naumov GN; Bao L; Contreras CM; Li D; Chen L; Krishnamurthy J; Koivunen J; Chirieac LR; Padera RF; Bronson RT; Lindeman NI; Christiani DC; Lin X; Shapiro GI; Jänne PA; Johnson BE; Meyerson M; Kwiatkowski DJ; Castrillon DH; Bardeesy N; Sharpless NE; Wong KK
    Nature; 2007 Aug; 448(7155):807-10. PubMed ID: 17676035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth.
    Chen Z; Li JL; Lin S; Cao C; Gimbrone NT; Yang R; Fu DA; Carper MB; Haura EB; Schabath MB; Lu J; Amelio AL; Cress WD; Kaye FJ; Wu L
    J Clin Invest; 2016 Jun; 126(6):2267-79. PubMed ID: 27140397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-363-3p inhibits migration, invasion, and epithelial-mesenchymal transition by targeting NEDD9 and SOX4 in non-small-cell lung cancer.
    Chang J; Gao F; Chu H; Lou L; Wang H; Chen Y
    J Cell Physiol; 2020 Feb; 235(2):1808-1820. PubMed ID: 31332786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC.
    Hollstein PE; Eichner LJ; Brun SN; Kamireddy A; Svensson RU; Vera LI; Ross DS; Rymoff TJ; Hutchins A; Galvez HM; Williams AE; Shokhirev MN; Screaton RA; Berdeaux R; Shaw RJ
    Cancer Discov; 2019 Nov; 9(11):1606-1627. PubMed ID: 31350328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of NEDD9 is associated with altered expression of E-Cadherin, β-Catenin and N-Cadherin and predictive of poor prognosis in non-small cell lung cancer.
    Miao Y; Li AL; Wang L; Fan CF; Zhang XP; Xu HT; Yang LH; Liu Y; Wang EH
    Pathol Oncol Res; 2013 Apr; 19(2):281-6. PubMed ID: 23086683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-25 Promotes Cell Proliferation, Migration, and Invasion of Non-Small-Cell Lung Cancer by Targeting the LATS2/YAP Signaling Pathway.
    Wu T; Hu H; Zhang T; Jiang L; Li X; Liu S; Zheng C; Yan G; Chen W; Ning Y; Li Y; Lu Z
    Oxid Med Cell Longev; 2019; 2019():9719723. PubMed ID: 31316723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression.
    Gao Y; Zhang W; Han X; Li F; Wang X; Wang R; Fang Z; Tong X; Yao S; Li F; Feng Y; Sun Y; Hou Y; Yang Z; Guan K; Chen H; Zhang L; Ji H
    Nat Commun; 2014 Aug; 5():4629. PubMed ID: 25115923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration.
    Zheng X; Chi J; Zhi J; Zhang H; Yue D; Zhao J; Li D; Li Y; Gao M; Guo J
    Oncogene; 2018 Jan; 37(4):502-511. PubMed ID: 28967900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced activity of the CREB co-activator Crtc1 in LKB1 null lung cancer.
    Komiya T; Coxon A; Park Y; Chen WD; Zajac-Kaye M; Meltzer P; Karpova T; Kaye FJ
    Oncogene; 2010 Mar; 29(11):1672-80. PubMed ID: 20010869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas.
    Tsai LH; Chen PM; Cheng YW; Chen CY; Sheu GT; Wu TC; Lee H
    Oncogene; 2014 Jul; 33(29):3851-60. PubMed ID: 23995788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dependency of human and murine LKB1-inactivated lung cancer on aberrant CRTC-CREB activation.
    Zhou X; Li JW; Chen Z; Ni W; Li X; Yang R; Shen H; Liu J; DeMayo FJ; Lu J; Kaye FJ; Wu L
    Elife; 2021 Jun; 10():. PubMed ID: 34142658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CREB coactivator CRTC2 promotes oncogenesis in LKB1-mutant non-small cell lung cancer.
    Rodón L; Svensson RU; Wiater E; Chun MGH; Tsai WW; Eichner LJ; Shaw RJ; Montminy M
    Sci Adv; 2019 Jul; 5(7):eaaw6455. PubMed ID: 31355336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
    Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
    Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FBXO22 mediates polyubiquitination and inactivation of LKB1 to promote lung cancer cell growth.
    Zhu XN; He P; Zhang L; Yang S; Zhang HL; Zhu D; Liu MD; Yu Y
    Cell Death Dis; 2019 Jun; 10(7):486. PubMed ID: 31217475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.
    Carretero J; Shimamura T; Rikova K; Jackson AL; Wilkerson MD; Borgman CL; Buttarazzi MS; Sanofsky BA; McNamara KL; Brandstetter KA; Walton ZE; Gu TL; Silva JC; Crosby K; Shapiro GI; Maira SM; Ji H; Castrillon DH; Kim CF; García-Echeverría C; Bardeesy N; Sharpless NE; Hayes ND; Kim WY; Engelman JA; Wong KK
    Cancer Cell; 2010 Jun; 17(6):547-59. PubMed ID: 20541700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.